




(86) Date de dépôt PCT/PCT Filing Date: 2012/12/27  
(87) Date publication PCT/PCT Publication Date: 2013/08/08  
(45) Date de délivrance/Issue Date: 2020/11/10  
(85) Entrée phase nationale/National Entry: 2014/06/27  
(86) N° demande PCT/PCT Application No.: CU 2012/000009  
(87) N° publication PCT/PCT Publication No.: 2013/113296  
(30) Priorité/Priority: 2011/12/27 (CU CU/P/2011/0243)

(51) Cl.Int./Int.Cl. *C12Q 1/04* (2006.01),  
*C12Q 1/26* (2006.01), *C12Q 1/37* (2006.01)  
(72) Inventeurs/Inventors:  
PERDOMO MORALES, ROLANDO, CU;  
MONTERO ALEJO, VIVIAN, CU;  
PERERA BRAVET, ERICK, CU;  
CALERO CARBONELL, JORGE ERNESTO, CU;  
PARDO RUIZ, ZENIA, CU;  
PORTO VERDECIA, MARLENE, CU;  
VEGA HURTADO, YAMILE, CU  
(73) Propriétaires/Owners:  
CENTRO DE INVESTIGACION Y DESARROLLO DE  
MEDICAMENTOS (CIDEM), CU;

(54) Titre : COMPOSITION A BASE D'EXTRAIT D'HEMOCYTES DE HOMARD POUR LA DETECTION DE LIPOPOLYSACCHARIDES, DE PEPTIDOGLYCANES ET 1,3- $\beta$ -D-GLUCANES  
(54) Title: COMPOSITION FROM LOBSTER HEMOCYTE EXTRACT FOR DETECTION OF LIPOPOLYSACCHARIDES, PEPTIDOGLYCANS AND 1,3- $\beta$ -D-GLUCANS.



(57) Abrégé/Abstract:

The present invention relates to the field of pharmaceuticals, chemistry and biotechnology and, in particular, to a method for preparing a composition for detecting and measuring the concentration of endotoxins or lipopolysaccharides, peptidoglycans and

(73) Propriétaires(suite)/Owners(continued):UNIVERSIDAD DE LA HABANA, CU

(74) Agent: MACRAE & CO.

(57) Abrégé(suite)/Abstract(continued):

(1,3)- $\beta$ -D-glucans, using a lobster hemocyte extract as starting material, to the modifications of the composition for increasing the sensitivity thereof, and to the methods for measuring endotoxins, peptidoglycans and (1,3)- $\beta$ -D-glucans using said composition.

## (12) SOLICITUD INTERNACIONAL PUBLICADA EN VIRTUD DEL TRATADO DE COOPERACIÓN EN MATERIA DE PATENTES (PCT)

(19) Organización Mundial de la  
Propiedad Intelectual  
Oficina internacional(43) Fecha de publicación internacional  
8 de agosto de 2013 (08.08.2013)

WIPO | PCT

(10) Número de Publicación Internacional  
**WO 2013/113296 A1**(51) Clasificación Internacional de Patentes:  
*C12Q* 1/04 (2006.01) *C12Q* 1/37 (2006.01)  
*C12Q* 1/26 (2006.01)(21) Número de la solicitud internacional:  
PCT/CU2012/000009(22) Fecha de presentación internacional:  
27 de diciembre de 2012 (27.12.2012)

(25) Idioma de presentación: español

(26) Idioma de publicación: español

(30) Datos relativos a la prioridad:  
CU/P/2011/0243  
27 de diciembre de 2011 (27.12.2011) CU(71) Solicitantes: **CENTRO DE INVESTIGACION Y  
DESARROLLO DE LOS MEDICAMENTOS(CIDEM)**  
[CU/CU]; Avenida 26 No.1605 e/ Boyeros y Puentes  
Grandes Nuevo Vedado, Plaza, La Habana 10400 (CU).  
**CENTRO DE INVESTIGACIONES MARINAS**  
[CU/CU]; Calle 16 e/ 1ra y 3ra No. 114 Miramar Playa, La  
Habana 11300 (CU).

(72) Inventores; e

(71) Solicitantes : **PERDOMO MORALES, Rolando**  
[CU/CU]; Porvenir # 563 apto D entre Tejar y Dolores.  
Lawton. 10 de Octubre. CP 10700, La Habana 10700  
(CU). **MONTERO ALEJO, Vivian** [CU/CU]; San  
Francisco No. 209 entre San Anastasio y Lawton. Lawton.  
10 de Octubre CP 10700, La Habana 10700 (CU).  
**PERERA BRAVET, Erick** [CU/CU]; D'Strampes  
No.168 entre Estrada Palma y Libertad, Santos Suárez. 10  
de Octubre. CP 10500, La Habana 10700 (CU). **CALERO  
CARBONELL, Jorge Ernesto** [CU/CU]; San José 1260  
apto. 1 e/ Mazón y Ronda. Plaza de la Revolución. CP  
10600, La Habana 10600 (CU). **PARDO RUIZ, Zenia**  
[CU/CU]; Calle 124 # 7120 entre 71 y 81. Marianao. CP  
11500, La Habana 11500 (CU). **PORTO VERDECIA,  
Marlene** [CU/CU]; Ave. 19A # 20804 entre 208 y 210.  
Reparto Atabey. Playa. CP 11300, La Habana 11300 (CU).  
**VEGA HURTADO, Yamile** [CU/CU]; Calle Santovenia  
#113 entre Patria y Lindero. Cerro. CP 10600, La Habana  
10600 (CU).*[Continúa en la página siguiente]*

(54) Title: COMPOSITION FROM LOBSTER HEMOCYTE EXTRACT FOR DETECTION OF LIPOPOLYSACCHARIDES, PEPTIDOGLYCANS AND 1,3-BETA-D-GLUCANS

(54) Título : COMPOSICIÓN A PARTIR DE EXTRACTO DE HEMOCITOS DE LANGOSTA PARA LA DETECCIÓN DE LIPOPOLISACÁRIDOS, PEPTIDOGLICANOS Y 1,3-β-D-GLUCANOS.




Figura 1

(57) Abstract: The present invention relates to the field of pharmaceuticals, chemistry and biotechnology and, in particular, to a method for preparing a composition for detecting and measuring the concentration of endotoxins or lipopolysaccharides, peptidoglycans and (1,3)-β-D-glucans, using a lobster hemocyte extract as starting material, to the modifications of the composition for increasing the sensitivity thereof, and to the methods for measuring endotoxins, peptidoglycans and (1,3)-β-D-glucans using said composition.

(57) Resumen:

*[Continúa en la página siguiente]*

WO 2013/113296 A1

## WO 2013/113296 A1



(74) **Mandatario:** VÁZQUEZ D' ALVARÉ, Dánice;  
Ave. Ira. No.1001 Esq. a 10, Miramar, Playa, La Habana  
11300 (CU).

(81) **Estados designados** (*a menos que se indique otra cosa, para toda clase de protección nacional admisible*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Estados designados** (*a menos que se indique otra cosa, para toda clase de protección regional admisible*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), euroasiática (AM, AZ, BY, KG, KZ, RU, TJ, TM), europea (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Publicada:**

— con informe de búsqueda internacional (Art. 21(3))

La presente invención se relaciona con la farmacéutica, la química y la biotecnología, y en particular con un proceso para preparar una composición para detectar y medir la concentración de endotoxinas o lipopolisacáridos, peptidoglicanos y (1,3)-β-D-glucanos, con un extracto de los hemocitos de las langosta como material de partida, las modificaciones a la composición para incrementar su sensibilidad, así como los procesos para medir endotoxinas, peptidoglicanos y (1,3)-β-D-glucanos empleando dicha composición.

## COMPOSITION FROM LOBSTER HEMOCYTE EXTRACT FOR DETECTION OF LIPOPOLYSACCHARIDES, PEPTIDOGLYCANS AND 1,3- $\beta$ -D-GLUCANS.

### DESCRIPTION

The present invention relates to the field of chemical, pharmaceutical and biotechnology, particularly with the detection of microorganisms and structures associated to their cell wall such as lipopolysaccharides (LPS) or endotoxins from Gram negative bacteria, peptidoglycans (PG) from Gram negative and positive, and (1,3)- $\beta$ -D-glucans (BG) from fungi and yeasts. The present invention also has application in the assessment of microbial contamination in ultrapure water as that used in the semiconductor industry, and as a diagnostic tool for the clinical laboratory.

The innate immune system provides very effective response mechanisms for the detection of microorganisms through recognition of molecular structures preserved and shared by a great number of microbes. These structures known as pathogen-associated molecular patterns (PAMPs) are not found in the host and are essential for the survival or pathogenicity of microorganisms. Among the best-characterized PAMPs are LPS, BG and PG, among others [Medzhitov and Janeway, The New England Journal of Medicine, 343(5):338-344, 2000].

It has been long established that endotoxins are the most relevant PAMP or exogenous pyrogen for the pharmaceutical and biotechnological industries because of their remarkable biological potency, ubiquity, resistance to conventional sterilization methods, and high probability of contaminating parenteral solutions [Williams K.L. Endotoxin Relevance and Control Overview; in Williams, K.L. (eds). Endotoxins, Pyrogens, LAL Testing and Depyrogenation. Third edition. Healthcare Report, New York, London. 2007, 27-46]. Furthermore, they are the main responsible of endotoxic shock associated with sepsis caused by Gram negative bacteria, and constitute the first alarm signal indicating the presence of these bacteria to the innate immune system. Access of LPS into the bloodstream produces profound deleterious effects on human health, such as systemic inflammatory response syndrome (SIRS), multiple organ failure (MOF), shock, and death [Opal SM, Contrib Nephrol 167, 14 -24, 2010, Hodgson JC, J Comp Pathol 135, 157-175, 2006].

The Limulus Amebocyte Lysate test (LAL) has been widely used for the detection of bacterial endotoxins, especially in the quality control of parenteral pharmaceutical and biotechnological products (US 4107077, US 4279774, US 4322217, US 3954663, US 4038029, US 4188264, US 4510241, US 5310657).

The LAL reagent is prepared from an extract of amebocytes present in the hemolymph of horseshoe crabs. It consists of a cascade of trypsin-like serine peptidases, which is activated in presence of endotoxins and (1,3)- $\beta$ -D-glucans through the Factors C and G, respectively. The reagent is based on the clotting response of horseshoe crabs, which is part of its innate immune system. A similar system has not been found in other invertebrate species so far [Iwanaga S y Lee BL, J Biochem Mol Biol 38, 128-150, 2005].

Endotoxin-specific LAL reagents have been obtained by separating Factor G sensitive to (1,3)- $\beta$ -D-glucans, leaving remaining components of the enzymatic cascade of the LAL (US5401647, US5605806, US20030104501) or inhibiting its activation (US5047353, US5155032, US547984, US5702882, US5998389, US5179006).

Horseshoe crabs are marine arthropods known as living fossils because they have evolved little in the last 300 million years. There are four species of horseshoe crabs from which a similar reagent can be obtained.

The species *Tachypleus tridentatus*, *Tachypleus gigas* and *Carcinoscorpius rotundicauda* are exclusively in Asia. The small population of the last two has never sustained production of the reagent. Moreover, *Tachypleus tridentatus*, commonly known as Chinese horseshoe crab or tri-spine horseshoe crab, had a high population density along the coast of China, especially in the northern South China Sea and in region to the range of Hainan Island. However, recent studies on *T. tridentatus* in Taiwan, Japan, Hong Kong, Thailand and China, have indicated that populations have declined drastically almost to extinction. The main causes are overfishing and pollution of the seas.

Due to the low population density of the Asian species, the LAL reagent marketed is mostly obtained from *Limulus polyphemus*, also known as the American horseshoe crab. The *Limulus* inhabits the US Atlantic coast, from northern Maine to the Yucatan Peninsula and the Gulf of Mexico. The greatest population is found in Delaware Bay but there has been a drastic decline in its numbers and spawning activity [Widener JW and Barlow RB, Biological Bulletin (197): 300-302, 1999]. The main causes have been the habitat loss and use as bait in fishing for oysters and eels [Rudloe A, Journal of Invertebrate Pathology (42):167-176, 1983; Botton ML, Biologist (49): 193-198, 2002]. Mortality due to bleeding process for the preparation of LAL reagent ranged around 15% [Walls EA and Berkson J, Virginia Journal of Science 51(3):195-198, 2000], but has doubled in the past time, increasing the decline of its population.

According to FAO, due to the high price of the LAL reagent, the narrow range of distribution of horseshoe crabs, and the extremely long time it takes for them to reach sexual maturity, it is easy to reduce the horseshoe crab population below the recovery rate. The four species are in danger of extinction and are included on the Red List of the International Union for the Conservation of Nature and Natural Resources (IUCN).

Considering the current critical situation of the horseshoe crab population, the United States Atlantic States Maritime Fishing Commission (ASMFC) has regulated several aspects concerning fishing and exploitation of the *Limulus*. Regarding the LAL industry, established that specimens cannot be bled to death and must be returned to the capture site marked and in healthy condition within less than 72 hours. It also set annual quotas of animals to be used to produce LAL, and that mortality associated with their handling could not exceed 15% of this quota.

Globally it has raised the need to study alternatives for the detection of endotoxins and other pyrogens before the source of raw material, the hemolymph from *Limulus*, is no longer available. The establishments of annual quota of horseshoe crabs that can be used by the

industry to produce LAL, while its demand continues on the rise, coupled with the recession of the population, indicate that it is not possible to sustain the increase in capture and bleeding of horseshoe crabs to produce LAL reagent.

Patents US4229541, US5082782, US6790659 and US20030186432 describes the development of strategies for the in vitro culture of amebocytes as an alternative to the hemolymph of horseshoe crab as natural source of amebocytes for preparing LAL. To date there is no commercial reagent obtained in this way or a project for its obtaining.

On the other hand, through a novel methodology it has been successfully cloned and produced the recombinant of the endotoxin-sensitive Factor C from the Singapore horseshoe crab, *Carcinoscorpius rotundicauda*. (US 5712144, US 5858706, US 5985590), and has been established its use for the detection and quantitation of LPS or endotoxin in a similar approach to the natural LAL reagent (US 6645724). It have been patented reagent formulations that combine the recombinant Factor C and detergents (US20030054432) or recombinant Factor C or that obtained by purification from natural source in formulations that exhibit increased sensitivity and stability (US20040235080). However, due to the lack of other enzymes naturally present in the reagent, these formulations lack the sensitivity provided by the amplifier effect of the enzymatic cascade, which has been partially solved by employing more sensitive fluorescent substrates. Other components of the LAL cascade such as the clotting enzyme (US20090208995) and the Factor G (US2010011266) have also been produced recombinant.

The LAL reagent and the recombinant Factor C are able to detect LPS, but do not detect PG. However, recent studies show the urgent need to also detect and control the content of PG in formulations for parenteral use, and other solutions and devices that should be non-pyrogenic. The PG are well-conserved components of cell wall of Gram positive and negative bacteria, and are the main responsible for the inflammatory response and its deleterious health consequences caused by Gram positive organisms, including septic shock [Silhavy TJ et al., Cold Spring Harbor perspectives in biology 2, a000414, 2010]. As the LPS, the PG are able to induce the release of proinflammatory cytokines [Verhoef J and Mattsson E, Trends in Microbiology 3:136-140, 1995; Teti G, Trends in Microbiology 7:100-101, 1999], are pyrogenic, released into the environment during growth and death of bacteria, and are resistant to ordinary means of sterilization [Moesby L, European Journal of Pharmaceutical Science 35, 442-446, 2008]. Due to the similarities between LPS and PGs it has been proposed that both be granted the same importance [Myhre AE et al., Shock 25 (3):227-35, 2006].

Moreover, the presence of PG can markedly sensitize the inflammatory response induced by LPS by synergism [Takada H et al., Journal of Endotoxin Research 8, 337-342, 2002; Hadley JS et al., Infection and Immunity, 73: 7613-7619, 2005; Wray GM, Shock,15(2):135-42, 2001; Shikama Y et al., Innate Immunity, 17(1):3-15, 2009] or by additive effect [Sprong T, Journal of Leukocyte Biology,70:283-288, 2001].

Like the LAL cascade for horseshoe crabs, the prophenoloxidase activating system (ProPO system) is an essential component of the humoral innate immune response of invertebrates [Cerenius et al., Trends Immunol. (29):263-271, 2008]. The ability of proPO system to

recognize PAMPs through a biosensor(s) and produce a visible and quantifiable response by measuring the enzymatic activity of the prophenoloxidase activating enzyme (ppA) or the phenoloxidase, makes it an attractive candidate for the development of a reagent for the detection of microorganisms and their PAMPs.

The ProPO system comprises a complex array of proteins including pattern-recognition proteins, the ppA and proPO. It has been described in several arthropods that the proPO system is activated in the presence of small amounts of PAMP through a mechanism that has not been fully elucidated. In general, it is known that in presence of PAMP the pro-ppA become active and, through proteolytic attack, converts prophenoloxidase (inactive zymogen) into active phenoloxidase. The phenoloxidase oxidizes monophenols and/or *o*-diphenols to aminechromes, initiating the synthesis of melanin.

In U.S. Patent 497052 it is described the development and use of a reagent obtained from the plasma of silkworm larvae (SLP) for the detection of BG and PG by determining phenoloxidase activity or ppA peptidase activity. It also comprises reagent modifications pursuing the specific determination of BG or PG. Based on this invention, U.S. Patent 5585248 describes the use of synthetic sensitive chromogenic substrates for detecting ppA activity. In U.S. Patent 6274565 BI is protected a modification of the reagent that allows specific detection of PG by inhibiting the activation pathway mediated by BG. The assay SLP appears to be particularly useful in the detection of bacterial contamination in platelets (U.S. 7598054 B2).

Also making use of the proPO system, US patents 6987002 B2 and 2002/0197662 A1 describe a reagent obtained from whole hemolymph of insect larva (*Tenebrio molitor* or *Holotrichia diomphalia*) for detection and quantification of (1,3)- $\beta$ -D-glucans.

The proPO system in the spiny lobster *P. argus* is found in the hemocytes [Perdomo-Morales et al., Fish Shellfish Immunol (23):1187-1195, 2007], and is capable of being activated in the presence of low concentrations of PG, BG and LPS. There are at least two peptidases related with the activation of proPO zymogen, one is calcium-dependent and the other not. The proPO system is regulated by a peptidase inhibitor of 5 kDa and net positive charge. The separation of the inhibitor from the active components of the system substantially increases the sensitivity of the response to PG, BG and LPS. The proPO system of the lobster also includes a LPS and BG recognizing protein (LGBP), which is localized in the plasma fraction of hemolymph. LGBP become activated upon binding to LPS and BG and is capable to increase the phenoloxidase activity in the lysate by increasing ppA activity.

The composition we are presenting here for first time, consist in an aqueous extract of hemocytes from the hemolymph of lobsters, hereafter referred as Lobster Hemocyte Lysate (LHL). The active component of interest in the LHL is the proPO system, and the composition is directed to the detection and quantitation of LPS, PG and BG. The term lobster or lobsters in this document refers to species listed within an infraorder selected from the group consisting of Astacidea, Palinura, Achelata, Thalassinidea, and Reptantia (macrura), Order Decapoda, class Crustacea, Phylum Arthropoda.

Although lobsters are also subject to overfishing in some regions, are very abundant species representing the major fishery resource in many countries (eg, Cuba, Brazil, Australia, USA,



etc.). Production of the present composition does not affect the availability of these animals for human consumption as food because the hemolymph is a byproduct that is usually discarded. Lobster is one of the largest crustaceans, and presents a significant volume of hemolymph readily available.

For the preparation of LHL, the hemolymph is withdrawn using a suitable anticoagulant that prevent plasma coagulation, but preferably that avoid both plasma clotting as well as the activation and clump of cells. As anticoagulants can be used an isotonic solution containing methyl xanthine derivatives such as theophylline, theobromine or caffeine, or salts thereof, or reagents capable of modifying sulfhydryl groups (-SH) as cysteine, iodoacetamide and N-ethylmaleimide. Also suitable are solutions containing chelating agents, having a pH between 4.5-8 provided by a suitable buffer, for example, the modified Alsever anticoagulant (27 mM sodium citrate, 336 mM NaCl, 115 mM glucose, 9 mM EDTA, pH 7) or citrate-EDTA anticoagulant (0.4 M NaCl, 0.1 M glucose, 30 mM trisodium citrate, 26 mM citric acid and 10 mM EDTA, pH 4.6). Modified Alsever anticoagulant is preferred, using a proportion hemolymph: anticoagulant 1:1 (v/v).

The hemocytes are separated from plasma by centrifugation at 700 g for 10 min at 4 ° C. The plasma (supernatant) is discarded, and the sedimented hemocytes are washed to remove residual plasma components. For this purpose, the hemocytes are resuspended with anticoagulant to a volume no greater than that corresponding to the initial mixture of hemolymph: anticoagulant, followed by another identical centrifugation cycle. The hemocytes should be washed at least twice. The washed hemocyte pellet is suspended in lysis buffer, preferably with a volume between 1 and 10 ml. The lysis buffer may contain NaCl at a concentration between 0.001 and 600 mM, agents capable of stabilizing enzymes (stabilizers), and a pH between 5 and 8.5 provided by a suitable buffer that does not sequester divalent cations. The lysis buffer 50 mM Tris-HCl, pH 7.5, 450 mM NaCl is preferred.

The hemocytes are lysed using a suitable disruption method among those commonly used in biochemistry for preparation of cell extracts, which can be mechanical, chemical or enzymatic. Considering the characteristics of these cells, the most suitable rupture methods are osmotic shock, freeze/thawing, homogenization by stirring (vortex) or manual (Dounce and Potter-Elvehjem), and ultrasonication. The hemocytes homogenate is centrifuged at 13 000 rpm at 4 ° C for 30 min to obtain the clarified supernatant or LHL.

The present invention includes a modification for increasing the sensitivity of the LHL response to LPS, PG and BG. This modification is based on eliminating or inactivating peptidase inhibitors present in the LHL. The inhibitors can be removed by separation techniques based on molecular size and shape, charge or affinity. Preferably it will be employed procedures based on size exclusion as gel filtration chromatography, ultrafiltration and diafiltration. For gel filtration chromatography, resins with an exclusion limit between 10 and 60 kDa should be used, preferably 30 kDa. The chromatographic fractionation is performed at a flow rate between 3 and 60 cm/h, preferably at 9 cm/h, and the sample volume applied should be between 1 and 5% of the total column volume, preferably 3%. Under these conditions, the remaining active proteins of the proPO system elutes at the void volume of the

column. When using ultrafiltration and diafiltration, membranes with cutoff between 5 and 60 kDa are used, preferably between 10 and 40 kDa. The LHL without inhibitor is hereinafter referred to as modified LHL (LHL-M).

Both reagents, LHL and LHL-M are used for the detection of PG, BG and LPS. This detection is based on the activation of the proPO system in lobster (Figure 1). Therefore, the detection of PG, BG and LPS is performed by determining the enzyme activity of the active phenoloxidase (FO) or the peptidase activity of ppAs (Figure 1).

The phenoloxidase activity is determined using monophenolic substrates (eg tyramine, L-tyrosine, 4-hydroxyphenylacetic acid, 4-hydroxyphenylpropionic acid) or diphenolic substrates (eg dihydroxy-L-phenylalanine (L-DOPA), dopamine, 3,4-dihydroxyphenylacetic acid, 3,4-dihydroxyphenylpropionic acid, catechol and methyl catechol. It is determined preferably with 1.2 mM dopamine. The formation of colored products allows the phenoloxidase activity can be determined visually or spectrophotometrically.

The sensitivity of the method to determine the phenoloxidase activity can be increased by the combination of monophenolic or o-diphenolic substrates with 3-methyl-2-benzothiazoline hydrazine (MBTH) or Besthorn's hydrazone. The MBTH is a powerful nucleophilic agent that forms a stable coloured adduct with o-quinones generated by phenoloxidases (MBTH-quinone), with an extinction coefficient or molar absorptivity much larger than the corresponding aminechrome [Espín JC et al., Eur J Biochem, 267:1270-1279, 2000; Garcia-Molina F et al., J. Agric. Food Chem 55:9739-9749, 2007]. The MBTH is used at a final concentration between 0.3 to 15 mM, preferably 2 to 7 mM.

The peptidase activity of ppA induced by BG, LPS and PG is determined using chromogenic or fluorogenic substrates for trypsin-like serine proteases. These substrates are of general formula R-Y or R-Arg-Lys-Y, where Y is a chromophore like p-nitroaniline (p-NA) or a fluorophore such as 7-amido-4-methyl coumarin, rhodamine, or 7-amido-4-trifluoromethylcoumarin. R represents an L or D amino acid protected by its N-terminus by a protecting group, or a peptide comprising L or D amino acids, or their combination, protected at its N-terminus by a protecting group.

Assays for detection of PG, LPS and BG using the LHL or LHL-M reagent can be performed by kinetic, pseudo-kinetic or endpoint methods. The reaction can be detected by using conventional spectrophotometers and fluorimeters. However, due to higher sample throughput and saving of reagents, is preferred the using of microplate reader capable of reading 96 well microplates, equipped to read wavelengths in the visible, fluorescence, or those capable of performing both functions.

Kinetic assays are defined as the product detection in time immediately after the addition of all components of the reaction mixture including the substrate. Pseudo-kinetic assays are defined as those where the response is determined after substrate addition to a previously incubated reaction mixture. The endpoint assays are defined as the single reading of the response after a fixed time incubation of the reaction mixture with the substrate.

The reaction mixture should have a pH value between 6 and 9, preferably 7.5, and may or may not contain divalent cations. It should contain calcium, magnesium or manganese in a minimum concentration of 5 mM, preferably 50 mM. The test temperature should be between room temperature and 45°C, preferably 37°C.

The present invention also comprises the use of LGBP to increase the sensitivity of both LHL and LHL-M to BG and LPS. The LGBP may be included in the formulation of the reagent, or can be added later to the reaction mixture. The LGBP may be in a concentration range in the assay for the detection of LPS and BG between 3 to 200 µg/ml, preferably from 50 to 125 µg/ml.

The LGBP is obtained from plasma, which is also a plentiful byproduct from the preparation of LHL. After an isoelectric precipitation step [Vargas-Albores F et al., Comp Biochem Physiol B Biochem Mol Biol, 116(4):453-458, 1997], the LGBP can be purified by affinity chromatography using hydrophilic matrices bound to (1,3)-β-D-glucans [Vargas-Albores F et al., Comp Biochem Physiol B Biochem Mol Biol, 116 (4): 453-458, 1997], immunoaffinity [Duvic B and Söderhäll K, J Biol. Chem., 265(16): 9327-9332, 1990] or heparin [Jimenez-Vegas F et al., Fish Shellfish Immunol 13(3):171-181, 2002]. Preferably, heparin is used as ligand, allowing the obtaining of large amounts of pure LGBP in a single chromatographic step.

Figure 1. Schematic representation of the prophenoloxidase activating system (proPO system) in the spiny lobster, and principle for the detection of lipopolysaccharides (LPS), peptidoglycans (PG) and (1,3)-β-D-glucans (BG) using the Lobster Hemocyte Lysate (LHL). LGBP: Lipopolysaccharide and (1,3)-β-D-glucans binding protein.

Figure 2. Influence of concentrations of *o*-diphenolic substrates dopamine and L-DOPA on phenolixadase activity in the Lobster Hemocyte Lysate.

Figure 3. LHL response to lipopolysaccharides (LPS), (1,3)-β-D-glucans (BG) and peptidoglycans (PG). Panels A-C: phenoloxidase activity in arbitrary units (Δ OD 490 nm/min). Panels D-F presents lineal relation between phenoloxidase activity and microbial elicitor concentration. LPS (0.185-1850 ng/ml), BG (1.8-18000 ng/ml) and PG (0.19-19000 ng/ml). Onset time means the reaction time required to reach a specific optical density at 490 nm.

Figure 4. Influence of the MBTH in the sensitivity of phenoloxidase response. Left panel: Optical density at 490 nm after 1 h at 37°C (endpoint assay). Right panel: Reaction rate in absence (Control) and presence of different concentrations of MBTH.

Figure 5. Determination of proPO system response to LPS using chromogenic substrate for serine peptidase S-2222 (Bz-Ile-Glu(γ-OR)-Gly-Arg-pNA-HCl).

Figure 6. Separation of protease inhibitor from the active components of proPO system by gel filtration chromatography in a Sephadex G-50 column.

Figure 7. Phenoloxidase response of LHL lacking protease inhibitor using dopamine as substrate. Sensitivity of 0.01 ng/ml LPS.

Figure 8. Purification of LGBP by affinity chromatography in heparin-Sepharose CL-6B (Panel A). SDS-PAGE Electrophoresis (Panel B): Molecular weight marker (lane 1), whole plasma (lane 2), purified LGBP under reducing (lane 3) and non-reducing (lane 4) conditions. Proteins were stained with Coomassie Brilliant Blue R-250.

### **Examples:**

#### **Example 1:**

##### **Preparation of Lobster Hemocyte Lysate (LHL)**

Ten milliliters of hemolymph were obtained from the fourth walking leg coxa using 20 ml sterile and pyrogen-free disposable syringes containing 10 ml of cold anticoagulant solution. The anticoagulant used was Alsever modified solution composed by 27 mM sodium citrate, 336 mM sodium chloride, 115 mM glucose, 9 mM EDTA, pH 7 (1000 mOsmol). The mixture of hemolymph: anticoagulant was poured into 50 ml sterile and pyrogen-free polypropylene centrifuge tubes and centrifuged at 700 g and 4°C for 10 min. The supernatant containing plasma was discarded. Thereafter the pelleted hemocytes were washed to remove residual plasma components. To accomplish this, the hemocyte pellet was suspended with 20 ml of cold anticoagulant, and then the volume was raised up with anticoagulant to the original anticoagulant: hemolymph volume (50 ml), and centrifuged again as described above. The washing step was repeated once more. The washed hemocytes pellet was resuspended in 3 ml of lysis buffer composed by 50 mM Tris-HCl, 450 mM NaCl, pH 7.5, and then transferred to 13 mm x 10 cm borosilicate tubes. The hemocyte suspension was lysed by sonication using three cycles of 20 Watts for 10 seconds in ice bath. The hemocyte homogenate was centrifuged at 13 000 rpm for 30 min. at 4 °C to obtain the clarified LHL.

#### **Example 2:**

##### **Comparing the effect of dopamine and L-DOPA concentrations in the sensitivity of phenoloxidase response in the LHL**

The lysate (420 µl at 0.1 mg/ml) was incubated with 4.2 ml of 1 mg/ml bovine trypsin for 30 min at 37°C. Hundred microliters of this mixture were added to the wells of a microplate containing 150 µl of various concentrations of L-DOPA (0.3 to 8 mM) or dopamine (0.15 to 9 mM) in 50 mM Tris-HCl, pH 7.5. The phenoloxidase activity was determined kinetically at 490 nm for 20 min at 37°C in a microplate reader.

#### **Example 3:**

##### **Determination of PG, BG and LPS using the LHL through detecting the phenoloxidase activity by kinetic method**

The LHL (12 mg/ml) was diluted to 0.5 mg/ml with 50 mM Tris-HCl, pH 7.5. The assay was performed in 96-well flat-bottom microplates that were sterile and pyrogen free certified. The reaction mixture consisted of 150 µl of 50 mM Tris-HCl, pH 7.5, 50 mM CaCl<sub>2</sub>, 20 µl of LHL, and 50 µl of activator (LPS, PG or BG). Control was endotoxin free water. Finally, 50 µl of 3.75 mM

dopamine was added as substrate. Dopaminechrome formation was assessed kinetically at 490 nm during 1 h by reading every 15 sec at 37 ° C in a microplate reader. The reaction velocity ( $\Delta OD$  490/min) was determined from the linear portion of the plot between OD 490 nm vs. time. Alternatively, the onset time was determined as the time required for the reaction mixture to reach an absorbance value of 0.1. The plots of the logarithm of the onset time vs. the logarithm of PAMP concentration were lineal and useful for quantitative purposes.

#### **Example 4:**

##### **Effect of MBTH in increasing the phenoloxidase response in the LHL. Titration**

The LHL at 0.8 mg/mL was diluted to 0.1 mg/mL with 50 mM Tris-HCl, pH 7.5. The assay was performed in flat-bottom-well microplates. The reaction mixture consisted of 40  $\mu$ l of 50 mM Tris-HCl, pH 7.5, 160  $\mu$ l 1 mg/ml trypsin dissolved in 50 mM Tris-HCl, pH 7.5, 10  $\mu$ l of LHL and 40  $\mu$ l of MBTH dissolved in distilled water. This mixture was incubated for 20 minutes at 37 °C and finally 50  $\mu$ l of 3.75 mM dopamine were added to each well. The reaction was kinetically read at 490 nm for 1 h every 15 sec at 37 °C in a microplate reader.

#### **Example5:**

##### **Determination of LHL response against LPS using chromogenic substrates for serine peptidases**

Fifty microliters of LHL (1 mg/ ml) obtained as described in Example 1, but without sodium chloride in the lysis buffer, were combined with 150  $\mu$ l of 50 mM Tris-HCl, pH 7.5 buffers, and 50  $\mu$ l of LPS. Thereafter, 50  $\mu$ l of 0.6 mM chromogenic substrate S-2222 (Bz-Ile-Glu ( $\gamma$ -OR)-Gly-Arg-pNA-HCl) were added to each well. The p-nitroaniline released was kinetically detected at 405 nm for 1 h at 37 °C.

#### **Example 6:**

##### **Protease inhibitor separation by gel filtration chromatography**

The protease inhibitor is separated from the active components of the proPO activating system in the LHL by using gel filtration chromatography on Sephadex G-50 superfine packed in a column XK 16/70 ( $V_t$  = 131.4 ml) that was previously equilibrated with 50 mM Tris-HCl, 0.2 M NaCl, pH 7.5. Four milliliters of 8 mg/ml LHL (3%  $V_t$ ) were fractionated at a flow rate of 0.3 ml/min. The chromatographic fractionations were monitored at 280 nm. The fraction corresponding to the void volume of the column was collected and designated as F1 or modified LHL (LHL-M).

#### **Example 7:**

##### **Protease inhibitor separation by spin column**

The LHL was fractionated on a spin column packed with Sephadex G-50 (1.5 ml). The column was equilibrated with 50 mM Tris-HCl, 450 mM NaCl, pH 7.5 buffers by washing the column 4

times at 1000 rpm for 1 min. One hundred and fifty microliters of LHL, prepared as in Example 1, were applied to the spin column and centrifuged at 1000 rpm for 1 min. The eluate was collected, and both the LHL (also named F0 fraction) and the eluate or fractionated LHL (also named F1 or LHL-M) were analyzed for protein concentration, inhibitory activity against trypsin, and phenoloxidase activity.

	Protein Concentration	
<b>F0</b>	150 $\mu$ l	9.7 mg/ml
<b>F1</b>	150 $\mu$ l	3 mg/ml
	Inhibitory Activity (IA)	
	IA/ml	IA/mg
<b>F0</b>	2378.81 $\pm$ 258.938	225.55 $\pm$ 36.586
<b>F1</b>	19.66 $\pm$ 0.277	6.598 $\pm$ 0.093
	Phenoloxidase Activity (PO)	
	PO/ml	PO/mg
<b>F0</b>	0.265 $\pm$ 0.0240	1.366 $\pm$ 0.01240
<b>F1</b>	0.089 $\pm$ 0.0090	1.483 $\pm$ 0.01650

#### **Example 8:**

##### **Determination of phenoloxidase response against LPS in LHL lacking trypsin-inhibitory activity or LHL-M**

The lysate without inhibitor (Modified LHL; LHL-M) was obtained according to Example 5. The reaction mixture with 50  $\mu$ l of LPS, 150  $\mu$ l of Tris-HCl, 50 mM CaCl<sub>2</sub>, pH 7.5, and 20  $\mu$ l of 0.8 mg/ml lysate (LHL-M) were incubated at 37 °C for 30 min. Finally, 50  $\mu$ l of 3.75 mM dopamine was added and the reaction progress was kinetically read at 490 nm for 1 hour at 37 °C. The onset time was calculated as the time required to reach an optical density of 0.3, then the log of onset time vs. log of LPS concentrations was plotted.

#### **Example 9:**

##### **Purification of Lipopolysaccharide and $\beta$ -1,3 Glucan Binding Protein (LGBP) from plasma**

The plasma obtained during the LHL preparation was centrifuged for clarification at 5000 rpm for 20 min at 4 °C. Hundred milliliters of clarified plasma were dialyzed vs. 5 L of distilled water at 4 °C for 48 hours using a dialysis membrane with a cutoff of 8000 Da. Four changes of dialyzing water every 12 hours were made during the period. The dialysate was centrifuged at 5000 rpm for 20 min at 4 °C and the supernatant was discarded. The protein pellet was suspended in 50 mM Tris-HCl, 0.2 M NaCl, pH 7.5 (Buffer A), and centrifuged again to remove the insoluble denatured proteins. Thirty-five milligrams of sample in 5 ml were applied to a column packed with Heparin-Sepharose CL-6B previously equilibrated in buffer A. After the

elution of unbound proteins, the column was washed with 2.5 column volumes of a mixture of Buffer A: Buffer B (60:40 v/v). Buffer B was composed by 50 mM Tris-HCl, 1 M NaCl, pH 7.5. Finally, LGBP was eluted with 5 column volumes with Buffer A: Buffer B (30:70 v/v). The chromatographic process was performed at a flow rate of 1 ml/min and the protein fractions were detected at 280 nm.

**CLAIMS:**

1. A composition for detecting one or more pathogen associated molecular patterns (PAMPs) selected from the group consisting of lipopolysaccharides (LPS), peptidoglycans and 1,3- $\beta$ -D-glucans (BG), said composition comprises an aqueous extract of lobster hemocytes containing the prophenoloxidase activating system (ProPO), said composition being substantially free of peptidase inhibitors having a molecular weight of about 5 kDa.
2. The composition of claim 1, wherein said composition is an aqueous extract of hemocytes from the hemolymph of lobsters.
3. The composition of claim 1, wherein the extract is from a lobster in an infraorder selected from the group consisting of Astacidea, Palinura, Achelata, and Thalassinidea.
4. The composition of claim 1, wherein said composition is rendered substantially free of peptidase inhibitors by removal or inactivation of a said peptidase inhibitors from said extract of lobster hemocytes.
5. The composition of claim 1, wherein said composition further comprises monophenol or o-diphenol substrates for activated phenoloxidase (PO) enzyme.
6. The composition of claim 5, wherein said monophenol substrates are selected from the group consisting of L-tyrosine, 4-hydroxyphenylacetic acid, and 4-hydroxyphenylpropionic acid, or wherein said o-diphenolic substrates are selected from the group consisting of dihydroxy-L-phenylalanine (L-DOPA), dopamine, 3,4-dihydroxyphenylacetic acid, 3,4-dihydroxyphenylpropionic acid, catechol and methyl catechol.
7. The composition of claim 6, wherein said composition further comprises 3-methyl-2-benzothiazolinone hydrazone in a concentration between 0.3 and 15 mM.



8. The composition of claim 1, wherein said composition further comprises chromogenic or fluorogenic substrates for trypsin.
9. The composition of claim 1, wherein said composition further comprises chromogenic or fluorogenic substrates prophenoloxidase activating enzyme (ppA).
10. The composition of claim 8 or 9, wherein said chromogenic or fluorogenic substrates are of general formula R-Y or R-Arg-Lys-Y, where Y is a chromophore or a fluorophore, and R represents an L or D amino acid protected at its N terminus by a protecting group, or a peptide comprising L and/or D amino acids protected at its N-terminus by a protecting group.
11. The composition of claim 1, wherein said composition further comprises a LPS and BG recognizing protein (LGBP) from a plasma fraction of hemolymph.
12. A process for preparing a composition as described in claim 1, said process comprises the steps of
  - withdrawing hemolymph from lobster;
  - separating hemocytes from plasma;
  - lysing the hemocytes to thereby provide an extract of lobster hemocytes containing the prophenoloxidase activating system (ProPO); and
  - removing or inactivating peptidase inhibitors having a molecular weight of about 5 kDa in said extract of lobster hemocytes to thereby render said extract substantially free of peptidase inhibitors.
13. The process of claim 12, wherein the step of withdrawing hemolymph and the step of separating hemocytes from plasma are performed in the presence of anticoagulants.

14. The process of claim 13, wherein said anticoagulants are selected from the group consisting of theophylline, theobromine, caffeine, cysteine, iodoacetamide, N-ethylmaleimide, modified Alsever anticoagulant, and citrate-EDTA anticoagulant.
15. The process of claim 12, wherein the step of removing peptidase inhibitors is performed by using separation techniques based on molecular size and shape, charge or affinity.
16. The process of claim 12, wherein the hemocytes are separated from the plasma by centrifugation or gravity, and subsequently washed and lysed in a lysis buffer containing sodium chloride at a concentration between 0.001 and 600 mM and enzyme stabilizing agents.
17. The process of claim 12, wherein the hemocytes are lysed by osmotic shock by freeze/thawing, by stirring, by manual homogenization, or by ultrasonication.
18. A process for detecting one or more pathogen-associated molecular patterns (PAMPs) selected from the group consisting of lipopolysaccharide (LPS), peptidoglycans and 1,3  $\beta$ -D glucans (BG) in a sample, said process comprising the steps of:
- providing a lysate of lobster hemocytes containing the prophenoloxidase activating (ProPO) system; wherein said ProPO system in said lysate, can be activated by each one of said PAMPs upon contact;
  - modifying said lysate by removing or inactivating peptidase inhibitors present in said lysate, to thereby provide a modified lysate of lobster hemocytes containing the ProPO system;
  - contacting a sample with said modified lysate of lobster hemocytes containing the ProPO system, so as to form a reaction mixture; and
  - detecting one or more of said PAMPs in said sample by measuring in said reaction mixture the peptidase activity of the prophenoloxidase activating enzyme or the activity of the phenoloxidase enzyme of said ProPO system; wherein said lysate of lobster hemocytes is from a lobster in an infraorder

selected from the group consisting of Astacidea, Palinura, Achelata, and Thalassinidea; and

wherein said step of modifying said lysate comprises the removal or inactivation of a peptidase inhibitor having a molecular weight of about 5 kDa.

19. The process according to claim 18, wherein the peptidase activity of the prophenoloxidase activating enzyme is determined with a chromogenic or fluorogenic substrate for trypsin.

20. The process according to claim 18, wherein the peptidase activity is measured spectrophotometrically by kinetic, pseudo-kinetic or endpoint methods.

21. The process according to claim 18, wherein said step of contacting further comprises the step of

adding to the reaction mixture an amount of between 3 and 200 µg/ml of lipopolysaccharide and 1,3-B-D-glucan binding protein (LGBP), isolated from the plasma of a lobster, so as to substantially increase the sensitivity of detection of LPS and BG.

22. The process according to claim 18, wherein said step of measuring in said reaction mixture the peptidase activity of the prophenoloxidase activating enzyme or the activity of the phenoloxidase enzyme of said ProPO system comprises kinetic, pseudo-kinetic or endpoint methods.

23. The process according to claim 18, wherein the activity of the phenoloxidase enzyme is measured using monophenolic or o-diphenolic substrates.

24. The process according to claim 23, wherein the monophenolic or o-diphenolic substrates further comprises 3-methyl-2-benzothiazolinone hydrazine (MBTH) in concentrations between 0.3 and 10 mM in the reaction mixture to increase the sensitivity of the phenoloxidase response.

25. The process according to claim 18, wherein said step of modifying said lysate comprises the removal of said peptidase inhibitors based on separation by molecular size and shape, affinity, immunoaffinity, or molecular charge.
26. The process according to claim 18, wherein said lysate of lobster hemocytes is a lysate of spiny lobster hemocytes.
27. The process according to claim 18, wherein said lysate of lobster hemocytes is a lysate of *Panulirus argus* hemocytes.




Figure 1.




Figure 2.




Figure 3.




Figure 4.




Figure 5.




Figure 6.




Figure 7.




Figure 8.

